AI Article Synopsis
- Amyloidosis is a group of diseases characterized by the buildup of insoluble proteins in various tissues and organs, affecting heart function.
- Cardiovascular amyloidosis can arise from primary causes, be part of systemic amyloidosis, or originate from chronic conditions elsewhere in the body, often presenting as heart failure and electrical conduction issues.
- Despite progress in imaging and sampling techniques that reduce the need for invasive procedures, the overall outlook for patients with amyloidosis remains poor and is influenced by the specific type of the disease.
Article Abstract
Amyloidosis comprises a unique group of diseases that share in common the extracellular deposition of insoluble fibrillar proteins in organs and tissues. Cardiovascular amyloidosis can be primary, a part of systemic amyloidosis, or a result of chronic systemic diseases elsewhere in the body. The most common presentations are congestive heart failure-mainly a restrictive infiltrative pattern--and conduction system disturbances. Recent developments in imaging techniques and extracardiac tissue sampling have minimized the need for invasive endomyocardial biopsy for amyloidosis. Despite advances in treatment, the prognosis for patients with amyloidosis is still poor and depends on the underlying disease type. Herein, we present new insights and recent advances in cardiovascular amyloidosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1163465 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!